

Practitioner's Dock t N . MPI01-019P1RNM

Serial No. 10/074,547

REMARKS

In response to the Restriction Requirement mailed October 15, 2003 (Paper No. 7) Applicants hereby elect Group I (claims 1-7, 12), drawn to an isolated nucleic acid, a recombinant vector comprising said nucleic acid, a recombinant host cell comprising said vector, and a method of producing the encoded polypeptide, classified in class 435, subclass 69.1. Applicants have amended claims 1 and 12 and have added new claims 23 - 25 drawn to the subject matter of Group I. Support for the new claims 23-25 can be found in the claims and application as filed. No new matter has been added. Claims 1-7, 12, and 23-25 are pending.

Applicants hereby reserve the right to traverse the above restriction with respect to non-elected Groups II - V claims (withdrawn claims 8-11, 13-22) in this or subsequent applications.

This paper is being filed timely within the one month period for response. No extensions of time are required. In the event any extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

10 November 2003

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Tracy M. Sioussat, Ph.D.  
Registration No. 50,609  
75 Sidney Street  
Cambridge, MA 02139  
Telephone - 617-374-7679  
Facsimile - 617-551-8820

(Page 5 of 5)